Conclusion: However, limited data on long-term safety, optimal dosing strategies, and durability of treatment effects warrant caution. Future research should evaluate extended treatment duration, dose-response relationships, and patient-reported outcomes to establish comprehensive clinical utility.
Tesamorelin side effects
Across 265 first-hand reports, people mentioned a side effect 28 times (about 11 per 100 reports). The most common: water retention, allergic reaction, anaphylaxis. User reports show what people notice — they can't tell you whether Tesamorelin is safe for you.
High-risk compound. Not an approved supplement; serious and sometimes irreversible risks, banned in sport, may be restricted where you live.
Reported side effects
What got worse for some people
In their own words
“I had my bloodwork done while taking Tesa. Never had any result like that.”
“I did an eight week cycle of tesamorelin 2mg/day on week days, weekends off, and it went really well. I definitely lost fat, gained muscle, and I look and feel a ton healthier.”
“It definitely worked for me to target visceral fat but I’m one of the people who had a lot of weight to lose.”
“Lost 25% of my visceral fat (Dexa). The water retention and joint pain was a little annoying but worth it.”
“As soon as I started the Tesamorline my sleep deteriorated. My sleep scores when from 70/80’s out of 100 to 20-30’s, sometimes way worse.”
Is Tesamorelin safe? What the research covers
Conclusion: Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy, without serious side effects or perturbation of glucose.
Conclusion: Our review indicates that, based on the findings of the 10 included studies, GH axis treatments are effective in reducing VAT and increasing LBM in patients with HIV-associated lipodystrophy. However, clinicians must decide whether the attributed benefits are clinically significant, considering the costs and potential risks of GH axis treatments. A limitation of this study is the small number of studies available of each GH axis drug class.